Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial
Authors:
- 1 January 2018
- journal article
- research article
- Vol. 16 (4) , 387-391
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarinThrombosis and Haemostasis, 2016
- Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registryBlood, 2014
- Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcomeJournal of Thrombosis and Haemostasis, 2013
- All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial FibrillationJournal of Managed Care Pharmacy, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)The Lancet, 1996